Treatment of recurrent or metastatic gastrointestinal stromal tumor: surgery or not / 中华胃肠外科杂志
Chinese Journal of Gastrointestinal Surgery
;
(12): 225-227, 2012.
Article
in Chinese
| WPRIM
| ID: wpr-290817
ABSTRACT
Currently, the treatment of recurrent or metastatic gastrointestinal stromal tumor(GIST) has become a tremendous challenge. Some international clinical trials revealed that imatinib might significantly improve the survival of patients with recurrent or metastatic GIST. Though the combination of surgery and imatinib has become an ideal treatment of metastatic GIST, there still exist some controversies regarding how to combine the two methods. Imatinib may influence the blood coagulation mechanism, therefore it is suggested that imatinib cessation should be performed a week before operation. Cytoreductive surgery has some clinical effects on recurrent or metastatic GIST, which can be combined with targeted therapy. Furthermore, the clinical trial for recurrent or metastatic GIST needs further evaluation.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Piperazines
/
Pyrimidines
/
General Surgery
/
Benzamides
/
Combined Modality Therapy
/
Therapeutic Uses
/
Gastrointestinal Stromal Tumors
/
Drug Therapy
/
Imatinib Mesylate
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Gastrointestinal Surgery
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS